Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Cash & Equivalents (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Cash & Equivalents for 3 consecutive years, with $38.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 1178.17% to $38.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.3 million through Dec 2025, up 1178.17% year-over-year, with the annual reading at $38.3 million for FY2025, 1178.17% up from the prior year.
  • Cash & Equivalents hit $38.3 million in Q4 2025 for Connect Biopharma Holdings, up from $37.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $105.7 million in Q4 2023 to a low of $3.0 million in Q4 2024.
  • Historically, Cash & Equivalents has averaged $45.5 million across 3 years, with a median of $39.5 million in 2025.
  • Biggest five-year swings in Cash & Equivalents: crashed 97.16% in 2024 and later skyrocketed 1178.17% in 2025.
  • Year by year, Cash & Equivalents stood at $105.7 million in 2023, then plummeted by 97.16% to $3.0 million in 2024, then surged by 1178.17% to $38.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for CNTB at $38.3 million in Q4 2025, $37.8 million in Q3 2025, and $40.6 million in Q2 2025.